Ingredient or product comparison
Best Peptides to Lose Face Fat Ranked: Clinical Evidence Comparison
Tirzepatide Dual GIP/GLP-1 receptor agonist 20.9% total body weight at 72 weeks (SURMOUNT-1) Visible changes at 12–16 weeks when body fat drops 10%+ GI side effects in 30–40% during titration; contraindicated with MTC history Strongest clinical evidence for sy
This source-based comparison does not add ratings or recommend a winner.
- Tirzepatide
- Dual GIP/GLP-1 receptor agonist
- 20.9% total body weight at 72 weeks (SURMOUNT-1)
- Visible changes at 12–16 weeks when body fat drops 10%+
- GI side effects in 30–40% during titration; contraindicated with MTC history
- Strongest clinical evidence for systemic fat loss; indirect facial contouring through sustained weight reduction
- Semaglutide
- GLP-1 receptor agonist
- 14.9% total body weight at 68 weeks (STEP-1)
- Visible changes at 14–18 weeks with consistent dosing
- Nausea, vomiting in 25–35% during dose escalation; resolves in 4–8 weeks
- FDA-approved for weight management; proven efficacy with established safety data
- CJC-1295 + Ipamorelin
- Growth hormone secretagogue combination
- 8–12% body fat reduction at 24 weeks (growth hormone deficiency studies)
- Visible changes at 16–20 weeks with resistance training protocol
- Minimal GI effects; transient water retention in first 2–4 weeks
- Indirect fat loss via elevated GH pulses; requires consistent dosing 5–7 days/week
- Liraglutide
- 8.4% total body weight at 56 weeks (SCALE trial)
- Visible changes at 18–24 weeks
- Similar GI side effect profile to semaglutide; daily dosing required
- Daily injection requirement limits compliance; lower efficacy than weekly semaglutide
- AOD-9604
- Modified GH fragment targeting fat metabolism
- Limited clinical data; animal studies show 15–20% visceral fat reduction
- No human facial contouring timeline established
- Minimal side effects in small human trials; lacks Phase 3 data
- Mechanism plausible but evidence base insufficient for clinical recommendation
- The comparison above ranks peptides by strength of clinical evidence for systemic fat loss. The indirect mechanism by which facial adipose tissue decreases. Tirzepatide and semaglutide dominate because they have completed large-scale Phase 3 randomised controlled trials with published endpoints. Growth hormone secretagogues like CJC-1295/ipamorelin show consistent fat loss in smaller cohorts but lack the trial scale of incretin mimetics. AOD-9604 remains experimental. The mechanism targets lipolysis directly, but human data is sparse.